30 Mai 2024
11.7 Acceleration towards the Sustainable Development Goal targets for maternal health and child mortality
STATEMENT
Delivered by Hillary Mutungi
The Medicines Patent Pool recognises the importance of access to quality-assured and affordable medicines to reduce maternal and child mortality, and of the availability of optimal paediatric medicines in adapted formulations.
As a founding member of the Global Accelerator for Paediatric Formulations network, MPP welcomes the inclusion of two operational paragraphs addressing paediatric medicine formulations in the proposed resolution, marking a significant step forward in prioritising the needs of children.
MPP is also committed to enhancing access to essential medicines for maternal health, demonstrated by our recent memorandum of understanding and conditional licensing agreement with Ferring on access to heat-stable carbetocin for post-partum haemorrhage.
MPP remains committed to facilitating access to essential medicines in collaboration with WHO and Member States. Together, we can ensure that children and mothers receive the care they need, contributing to better health outcomes for future generations.
Agenda Item: 7
11.2 Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases
Prevention and management of noncommunicable diseases, promotion of mental health and well-being, and treatment and care of mental health conditions
The Director-General submits this report pursuant to the request of the Health Assembly in decision WHA72(11) (2019) on follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases “to consolidate reporting on the progress achieved in the prevention and control of noncommunicable diseases and the promotion of mental health with an annual report to be submitted to the Health Assembly through the Executive Board, from 2021 to 2031, annexing reports on implementation of relevant resolutions, action plans and strategies, in line with existing reporting mandates and timelines”
The Medicines Patent Pool (MPP) welcomes the opportunity to comment on the report on the follow-up to the political declaration from the third high-level meeting on the prevention and control of NCDs[1] and notes that improving availability of affordability of essential medicines, including generics, is a key element of the document.
MPP is dedicated to accelerating access to innovative essential medicines in their generic and biosimilar versions through voluntary licensing and technology transfer, to improve affordability, availability and to support regional manufacturing.
To achieve this, MPP remains committed to collaborating with WHO, Member States, and other stakeholders to identify priorities, create a favorable environment for licensing and technology transfer and support the achievement of universal health coverage.
[1] https://apps.who.int/gb/ebwha/pdf_files/EB154/B154_7-en.pdf
13.3 Working Group on Amendments to the International Health Regulations (2005)
13.4 Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response
Delivered by Tiwa Braimoh
As an organisation dedicated to improving access to affordable innovative medicines and other health technologies in low- and middle-income countries, the Medicines Patent Pool (MPP) is pleased to observe the consistent recognition of the importance of ensuring timely and equitable access to pandemic-related products all through the WGIHR and INB processes.
MPP would like to commend the efforts of the leadership of the two processes and all stakeholders and hopes that the negotiations will resume and be concluded soon.
In the meantime, MPP remains available to offer support in anyway needed, including sharing from its experience and expertise in licensing as well as its work with the WHO on the mRNA Technology Transfer programme.
Département communication, presse et médias
Le Medicines Patent Pool (MPP) est une organisation de santé publique soutenue par les Nations Unies qui œuvre à accroître l’accès à des médicaments innovants et à d’autres technologies de santé, et à en faciliter le développement, pour les pays à revenu faible et intermédiaire. Grâce à son modèle économique innovant, le MPP collabore avec la société civile, les gouvernements, les organisations internationales, l’industrie, les groupes de patients et d’autres parties prenantes afin de prioriser et d’octroyer des licences pour les produits de santé nécessaires, et de mettre en commun la propriété intellectuelle afin d’encourager la fabrication de médicaments génériques et le développement de nouvelles formulations.
À ce jour, le MPP a signé des accords avec 22 détenteurs de brevets couvrant 13 antirétroviraux contre le VIH, une plateforme technologique liée au VIH, trois antiviraux à action directe contre l’hépatite C, un traitement contre la tuberculose, un traitement contre le cancer, quatre technologies à action prolongée, un médicament contre l’hémorragie du post-partum, trois traitements antiviraux oraux contre la COVID-19 et 16 technologies liées à la COVID-19.
Le MPP a été fondé par Unitaid, qui demeure son principal bailleur de fonds. Les activités du MPP visant à améliorer l’accès aux médicaments essentiels sont également financées par l’Agence suisse pour le développement et la coopération (SDC), le gouvernement du Canada et Coefficient Giving. Les activités du MPP en matière de transfert de technologie sont menées avec le soutien financier du gouvernement japonais, du ministère français de l’Europe et des Affaires étrangères, de l’Agence allemande de coopération internationale, du gouvernement de la Flandre et de la SDC.